Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof

A tablet for oral administration comprising:

• a. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) Form I, wherein the Compound 1 Form I is present in an amount ranging from 25 mg to 250 mg;
• b. a filler;
• c. a disintegrant which is croscarmellose sodium and is present in an amount of about 6 wt % to about 10 wt % by weight of the tablet;
• d. a surfactant;
• e. a lubricant;
• and
• f. a binder.

A method of treating cystic fibrosis in a subject, comprising administering a tablet for oral administration comprising:

• a. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) Form I wherein the Compound 1 Form I is present in an amount ranging from 25 mg to 250 mg;
• b. a filler;
• c. a disintegrant;
• d. a surfactant which is sodium lauryl sulfate and is present in an amount of 0.3 wt % to 2 wt % by weight of the tablet;
• e. a lubricant;
• and
• f. a binder.

A method of treating cystic fibrosis in a subject, comprising administering a tablet for oral administration comprising:

• a. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) Form I wherein the Compound 1 Form I is present in an amount ranging from 25 mg to 250 mg;
• b. a filler;
• c. a disintegrant;
• d. a surfactant;
• e. a lubricant;
• and
• f. a binder;
• wherein Compound 1 Form I is present in an amount of 30 wt % to 70 wt % by weight of the tablet.